PTEN and lung adenocarcinoma: PPARγ agonist efatutazone and gefitinib have been indicated to synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway [34].